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Background
Pre-clinical and clinical data demonstrate the effectiveness
of combining RT and CpG immunotherapy. There is data
to suggest that the effectiveness of CpG immunotherapy
may be limited by induction of the immunosuppressive
enzyme, IDO. We test the efficacy and safety of combining
RT and CpG with blockade of the immunosuppressive
enzyme, IDO, using 1-Methyl D-Tryptophan (1-MT).
Methods
Tumor bearing mice were treated with RT + IT. IT con-
sisted of intratumoral CpG and 1-MT administered in the
drinking water. Tumor growth, survival, toxicity and the
immune profile of various tissues were assessed. Based on
preliminary results a similar clinical trial was initiated at the
UC Davis Veterinary Cancer Center testing this approach
for spontaneous metastatic cancers in companion canines.
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Results
In mice therapy improved overall survival, decreased lung
metastases, decreased mean tumor growth, increased
percentage of activated dendritic cells in tumor draining
lymph nodes, and decreased levels of regulatory T-cells.
No treatment related toxicities were observed.
In the canine clinical trial 6 patients have been enrolled
to date. No treatment related toxicities have been observed.
Preliminary results indicate a robust response at the pri-
mary treated disease site but also indicate the induction of
systemic anti-tumor immunity as demonstrated by regres-
sion or stability of un-irradiated metastatic disease. The
treatment has drastically reduced the level of regulatory
T-cells in the tumor, draining lymph nodes, and peripheral
blood in some animals.
Conclusions
Combining RT and IT is more effective than either ther-
apy alone. Preliminary results in spontaneous canine can-
cers also show promise. Further study is needed to
determine the immunologic mechanism of this therapy.
This therapy has limited toxicity in both mice and canines
and is being considered for translation to human studies.
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